Alloplant
|
WikiDoc Resources for Alloplant |
|
Articles |
|---|
|
Most recent articles on Alloplant |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Alloplant at Clinical Trials.gov Clinical Trials on Alloplant at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Alloplant
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Alloplant Discussion groups on Alloplant Directions to Hospitals Treating Alloplant Risk calculators and risk factors for Alloplant
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Alloplant |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Alloplant is an experimental, chemically processed biomaterial used for transplantation. It is subjected to radiating sterilization and is being studied for possible regeneration of tissues of the recipient.
The primary advocate for alloplants is Russian surgeon Ernest Muldashev. In 2000, he claimed to have successfully transplanted a human eye into a blind woman using a harvested cornea and retina combined with an alloplant. The claim was widely rejected by the scientific and medical community. Although they avoid the use of the term "quack", doctors interviewed by The Guardian maintain that such transplants are medically impossible and not supported by peer-reviewed medical evidence.[1]